Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, Mantle-Cell

ClinicalTrials.gov lists 1,208 trials for Lymphoma, Mantle-Cell or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 100.

MeSH D020522 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 363 Phase 1/2 Phase 1/2 169 Phase 2 Phase 2 428 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 81 Phase 4 Phase 4 6 Not applicable Not applicable 70 Observational Observational 80 Phase 1 Phase 1 363 Phase 1/2 Phase 1/2 169 Phase 2 Phase 2 428 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 81 Phase 4 Phase 4 6 Not applicable Not applicable 70 Observational Observational 80

Trials per phase (log scale)

2 more sections with rows

1,208 of the 1,208 trials are tagged with Lymphoma, Mantle-Cell itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, Mantle-Cell report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, Mantle-Cell trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 56

1990: 3 trials (Not applicable 1, Phase 2 2) 1991: 1 trials (Phase 2 1) 1992: 4 trials (Phase 2 3, Phase 1 1) 1993: 2 trials (Observational 1, Phase 2 1) 1994: 2 trials (Phase 1 2) 1995: 5 trials (Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 1996: 13 trials (Observational 2, Phase 2 6, Phase 1 5) 1997: 31 trials (Not applicable 2, Phase 3 6, Phase 2/3 1, Phase 2 10, Phase 1/2 3, Phase 1 9) 1998: 40 trials (Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 18, Phase 1/2 4, Phase 1 12) 1999: 47 trials (Observational 1, Not applicable 3, Phase 3 6, Phase 2 11, Phase 1/2 3, Phase 1 23) 2000: 46 trials (Not applicable 4, Phase 3 4, Phase 2 21, Phase 1/2 4, Phase 1 13) 2001: 29 trials (Not applicable 2, Phase 3 3, Phase 2 13, Phase 1/2 2, Phase 1 9) 2002: 38 trials (Observational 1, Not applicable 5, Phase 3 5, Phase 2 11, Phase 1/2 2, Phase 1 14) 2003: 30 trials (Observational 1, Not applicable 5, Phase 3 3, Phase 2 8, Phase 1/2 4, Phase 1 9) 2004: 47 trials (Observational 1, Not applicable 5, Phase 3 3, Phase 2 18, Phase 1/2 6, Phase 1 14) 2005: 56 trials (Observational 4, Not applicable 5, Phase 3 2, Phase 2 27, Phase 1/2 10, Phase 1 8) 2006: 41 trials (Observational 4, Not applicable 3, Phase 3 3, Phase 2/3 1, Phase 2 13, Phase 1/2 7, Phase 1 10) 2007: 56 trials (Other 1, Observational 4, Not applicable 5, Phase 3 3, Phase 2 20, Phase 1/2 5, Phase 1 18) 2008: 53 trials (Observational 11, Not applicable 1, Phase 3 6, Phase 2/3 1, Phase 2 17, Phase 1/2 7, Phase 1 10) 2009: 43 trials (Other 1, Observational 5, Not applicable 2, Phase 3 4, Phase 2 14, Phase 1/2 6, Phase 1 11) 2010: 45 trials (Observational 3, Not applicable 3, Phase 3 4, Phase 2 17, Phase 1/2 6, Phase 1 12) 2011: 36 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2 14, Phase 1/2 8, Phase 1 10) 2012: 31 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 15, Phase 1/2 2, Phase 1 10) 2013: 29 trials (Not applicable 1, Phase 3 3, Phase 2 9, Phase 1/2 6, Phase 1 10) 2014: 28 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 3, Phase 1/2 7, Phase 1 15) 2015: 32 trials (Observational 1, Not applicable 1, Phase 2 15, Phase 1/2 6, Phase 1 9) 2016: 42 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 10, Phase 1/2 11, Phase 1 13) 2017: 42 trials (Observational 4, Phase 3 3, Phase 2 13, Phase 1/2 10, Phase 1 12) 2018: 36 trials (Observational 7, Phase 2 7, Phase 1/2 6, Phase 1 16) 2019: 35 trials (Observational 5, Phase 4 1, Phase 3 1, Phase 2 14, Phase 1/2 6, Phase 1 8) 2020: 37 trials (Observational 5, Phase 2 12, Phase 1/2 8, Phase 1 12) 2021: 50 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 4, Phase 2 18, Phase 1/2 7, Phase 1 14) 2022: 28 trials (Observational 4, Not applicable 1, Phase 3 1, Phase 2 7, Phase 1/2 5, Phase 1 10) 2023: 37 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 9, Phase 1/2 5, Phase 1 16) 2024: 36 trials (Observational 4, Not applicable 1, Phase 3 2, Phase 2 16, Phase 1/2 3, Phase 1 10) 2025: 33 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 17, Phase 1/2 5, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 29
2025 33
2024 36
2023 37
2022 28
2021 50
2020 37
2019 35
2018 36
2017 42

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 36 trials starting in 2026 and about 32 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 105 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 855 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, Mantle-Cell trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 363
Phase 1/2 169
Phase 2 428
Phase 2/3 5
Phase 3 81
Phase 4 6
Not applicable 70
Observational 80
Expanded access 5
Unknown 1

How many Lymphoma, Mantle-Cell trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 22
Recruiting 113
Enrolling by invitation 3
Active, not recruiting 82
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, Mantle-Cell trials? (2)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 100
National Institutes of Health Clinical Center (CC) 13

Which drugs are being tested for Lymphoma, Mantle-Cell? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 200
Cytoxan 190
IBRUTINIB 64
Melphalan 56

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 132
Peripheral blood stem cell transplantation 102
Filgrastime (G-CSF) 84
Etoposid 71
Mofetil Mycophenolate 66

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, Mantle-Cell trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 568 77
Febrile neutropenia 552 84
Lymphocyte count decreased 453 13
Neutrophil count decreased 368 33
Death 274 28

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, Mantle-Cell? (284)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025 Yes
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood 2025 Yes
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. Blood advances 2025 Yes
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology 2025 Yes
Pirtobrutinib in Chinese patients with relapsed or refractory B-cell malignancies: A single-arm, open-label, phase 2, multicenter trial. International journal of cancer 2025 Yes

Showing 5 of 284 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (9)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Mantle cell lymphoma Annual incidence 1-9 / 1 000 000 United States US Exact
Mantle cell lymphoma Annual incidence 1-9 / 1 000 000 United States US Unspecified
Mantle cell lymphoma Annual incidence 1-9 / 1 000 000 United States US Exact
Mantle cell lymphoma Annual incidence 1-9 / 100 000 France Not stated Exact
Mantle cell lymphoma Annual incidence 1-9 / 100 000 France Not stated Unspecified

Showing 5 of 9 prevalence observations.

Start your 14-day trial Email me all 9 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Mantle cell lymphoma 52416 Exact Orphanet Rare Disease Ontology (ORDO)
Mantle cell lymphoma 52416 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages